Fatal Immune Checkpoint Inhibitor-related Pancreatitis

Intern Med. 2021 Dec 15;60(24):3905-3911. doi: 10.2169/internalmedicine.7366-21. Epub 2021 Jun 12.

Abstract

We herein report a case of fatal pancreatitis induced by an immune checkpoint inhibitor. A 62-year-old man with cancer of unknown primary was treated with pembrolizumab. After 12 cycles, immune-related pneumonitis developed and was treated with prednisolone. Three months later, pancreatitis developed, which was successfully treated with hydration and protease inhibitors. Eight months later, another attack of pancreatitis occurred, which did not respond to therapy, including high-dose corticosteroids, and he eventually died. This is the first report describing fatal immune checkpoint inhibitor-related pancreatitis. Despite the rarity of this complication, attention should be paid to its potential severity and treatment.

Keywords: acute pancreatitis; drug-induced pancreatitis; immune checkpoint inhibitor; immune-related adverse event; pembrolizumab.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Humans
  • Immune Checkpoint Inhibitors
  • Male
  • Middle Aged
  • Pancreatitis* / chemically induced
  • Pancreatitis* / diagnosis
  • Pancreatitis* / drug therapy
  • Pneumonia* / drug therapy
  • Prednisolone / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Immune Checkpoint Inhibitors
  • Prednisolone